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Abstract
Background:  In most patients with ovarian cancer, diagnosis occurs after the tumour has
disseminated beyond the ovaries. In these cases, post-surgical taxane/platinum combination
chemotherapy is the "gold standard". However, most of the patients experience disease relapse
and eventually die due to the emergence of chemotherapy resistance. Histone deacetylase
inhibitors are novel anticancer agents that hold promise to improve patient outcome.
Methods: We compared a prototypic histone deacetylase inhibitor, suberoylanilide hydroxamic
acid (SAHA), and paclitaxel for their treatment efficacy in ovarian cancer cell lines and in primary
patient-derived ovarian cancer cells. The primary cancer cells were isolated from malignant ascites
collected from five patients with stage III ovarian carcinomas. Cytotoxic activities were evaluated
by Alamar Blue assay and by caspase-3 activation. The ability of SAHA to kill drug-resistant 2780AD
cells was also assessed.
Results: By employing the cell lines OVCAR-3, SK-OV-3, and A2780, we established SAHA at
concentrations of 1 to 20 µM to be as efficient in inducing cell death as paclitaxel at concentrations
of 3 to 300 nM. Consequently, we treated the patient-derived cancer cells with these doses of the
drugs. All five isolates were sensitive to SAHA, with cell killing ranging from 21% to 63% after a 72-
h exposure to 20 µM SAHA, while four of them were resistant to paclitaxel (i.e., <10% cell death
at 300 nM paclitaxel for 72 hours). Likewise, treatment with SAHA led to an increase in caspase-3
activity in all five isolates, whereas treatment with paclitaxel had no effect on caspase-3 activity in
three of them. 2780AD cells were responsive to SAHA but resistant to paclitaxel.
Conclusion: These ex vivo findings raise the possibility that SAHA may prove effective in the
treatment of paclitaxel-resistant ovarian cancer in vivo.
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Background
Ovarian cancer is the most lethal gynaecological neo-
plasm, accounting for over 6% of deaths from cancer in
women [1]. The standard treatment is a combination of
surgery and chemotherapy, the latter usually consisting of
a taxane/platinum combination. By this regimen, initial
response rates of more than 80% are achieved [2]. Unfor-
tunately, in the vast majority of women, diagnosis occurs
after the disease has already disseminated beyond the ova-
ries. These patients typically relapse and eventually die as
the tumours become refractory to treatment. Actually,
drug resistance is supposed to account for therapy failure
and death in more than 90% of ovarian cancer patients
with advanced-stage at diagnosis [3]. Novel treatment
strategies to overcome drug resistance, thus, are urgently
needed.
Drug resistance is generally associated with altered gene
expression in the drug-resistant cancer cells in comparison
to the drug-sensitive cancer cells. Typically, resistant
tumour cells show an upregulation of antiapoptotic pro-
teins and a downregulation of proapoptotic proteins,
resulting in a ratio of anti- to proapoptotic proteins
favouring survival, as well as an elevated expression of
drug efflux pumps, such as P-glycoprotein (Pgp) [4]. In
ovarian cancer, cDNA microarray analyses of cisplatin-
resistant sublines of KF-1 cells [5] and paclitaxel-resistant
sublines of SK-OV-3 cells [6] have demonstrated tran-
scriptional changes in genes coding for such proteins.
Hence, treatment strategies aiming at reversing the aber-
rant expression of genes involved in drug response could
prove effective in the management of drug-resistant ovar-
ian cancer.
At present, considerable attention focuses on the role of
epigenetic modifications in carcinogenesis and the devel-
opment of drug resistance. As such, histone hypoacetyla-
tion has recently been recognized as an important type of
epigenetic alteration in human cancers [7]. Histone
hypoacetylation, which is associated with condensed
chromatin structure and gene silencing, is the result of the
aberrant actions of histone acetyltransferases and histone
deacetylases. Inhibitors of histone deacetylases (HDIs) are
currently emerging as a promising new class of anticancer
agents: they can reactivate gene expression and prevent
proliferation, activate differentiation, and/or induce
apoptosis of tumour cells [8]. In so doing, they e.g. reacti-
vate gene expression of dormant tumour suppressor
genes, such as CDKN1A (p21) [9].
The potent antitumour activity of HDIs has been observed
in cell lines originating from different types of human
cancers as well as in studies on mice xenograft models of
human neoplasia [10]. Importantly, HDIs have been
shown both in vitro and in vivo to affect cancer cells while
leaving normal cells comparatively unscathed [11,12]. In
addition, the clinical potential of these agents has been
documented by several Phase I trials of different HDIs in
patients with solid tumours or leukaemias [13-18]. With
respect to ovarian cancer, several preclinical studies have
demonstrated the anticancer efficacy of various HDIs in
cell lines in vitro [19-23] and in cell lines implanted into
nude mice [24,25]. However, no information is available
about the potential effectiveness of HDIs in primary ovar-
ian cancer cells from patients. Herein, we demonstrate
efficient  ex vivo activity of the HDI suberoylanilide
hydroxamic acid (SAHA) in patient-derived ovarian can-
cer cells, which display only marginal responsiveness to
paclitaxel.
Methods
Cell culture
OVCAR-3, SK-OV-3, A2780 and 2780AD ovarian carci-
noma cells were kindly provided by Dr. J. Braunger
(Altana Pharma, Konstanz, Germany). SK-OV-3 cells were
maintained in McCoy's 5a. OVCAR-3, A2780, and
2780AD cells were maintained in RPMI 1640. The
medium of OVCAR-3 cells was supplemented with 1.5 g/
l sodium bicarbonate, 1.0 mM sodium pyruvate, and 0.01
mg/ml bovine insulin; the medium of 2780AD cells was
supplemented with 2.2 µM doxorubicin (Sigma, Deisen-
hofen, Germany). All media were supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 units/ml
penicillin G sodium, and 100 µg/ml streptomycin sul-
phate (media and supplements were purchased from Bio-
chrom, Berlin, Germany). Cells were cultivated at 37°C in
a humidified 5% CO2 incubator and routinely passaged
when 90–95% confluent. Cell viability was determined by
the trypan blue exclusion test. Cells were regularly
inspected to be free of Mycoplasma with Mycoplasma detec-
tion reagents from Roche (Mannheim, Germany).
Isolation of primary ovarian cancer cells from ascites
The use of patient samples was approved prior to the ini-
tiation of these studies (University of Greifswald, Research
Ethics Committee), and all patients signed consent forms.
Ovarian cancer cells were isolated from malignant ascites
collected from patients with stage III ovarian carcinomas.
Of the five patients whose cells were used in this study,
four were untreated, and one had been treated with a sin-
gle dose of paclitaxel/carboplatin (isolate ASC-OC-4). The
four untreated patients were subsequently treated with a
palitaxel/carboplatin combination according to the stand-
ard protocol for the management of ovarian cancer.
The ascitic fluid was centrifuged at 3000 rpm at room tem-
perature for 10 minutes, and the cellular pellet was
washed twice in PBS. The pellet was resuspended in Ham's
F12K medium (Biochrom) supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 100 units/ml penicillin GBMC Cancer 2006, 6:183 http://www.biomedcentral.com/1471-2407/6/183
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sodium, and 100 µg/ml streptomycin sulphate, and
plated in T75 flasks. Ascitic fluid typically contains a con-
siderable number of blood cells; however, they do not
impede cell plating. After 3–4 weeks of culture, purity of
the ovarian carcinoma cells was at least 80%. All experi-
ments described here were performed at culture passages
4–7.
Cytotoxicity assay
The assays were performed in quadruplicate in 96-well
flat-bottom microtiter plates. After a 72-h incubation with
either SAHA (Alexis, Grünberg, Germany) or paclitaxel
(Sigma), 1/10 volume of Alamar Blue (Biosource, Solin-
gen, Germany) solution was added and cells incubated at
37°C for an additional 3 hours. The absorbance of the
wells was measured at 560/595 nm using a Wallac Victor
(Perkin Elmer, Rodgau-Jügesheim, Germany) fluorome-
ter. Results are expressed as a percentage of relative cell
numbers of control cells.
Caspase-3 activity
Caspase-3 activity was measured 24 hours after treatment
with drugs using the synthetic fluorogenic substrates Ac-
DEVD-AFC (Bachem, Heidelberg, Germany). Cells were
lysed in 10 mM Tris-HCl, 10 mM NaH2PO4/NaHPO4 (pH
7.5), 130 mM NaCl, 1% Triton-X-100, and 10 mM
Na4P2O7 and then incubated with 20 mM Hepes (pH 7.5),
10% glycerol, 2 mM DTT and 25 µg/ml Ac-DEVD-AFC at
37°C for 2 hours. The release of trifluoromethylcoumarin
(AFC) was analyzed on a Wallac Victor fluorometer using
an excitation/emission wavelength of 390/510 nm. Rela-
tive caspase activities were calculated as a ratio of emis-
sion of treated cells to untreated cells.
Cytofluorometric analysis of cell death
To determine cell death, cells were harvested after a 72-h
cultivation in the presence of drugs, followed by a 5-min
incubation in 2 µg/ml propidium iodide (PI) (Sigma) in
PBS at 4°C in the dark. PI uptake was assessed by flow
cytometry analysis on a Becton Dickinson (Heidelberg,
Germany) FACSCalibur using CellQuest software. 10,000
cells were analyzed in each sample; data were gated to
exclude debris. Cyclosporine A (CsA; Alexis) was applied
1 hour before treatment with SAHA or paclitaxel, respec-
tively.
Western blot analysis
Cell were lysed on ice for 15 minutes in 40 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, and 0.1% SDS supplemented with a pro-
tease inhibitor cocktail (Roche) followed by brief sonifica-
tion. Protein concentration was assayed using
bicinchoninic acid (Pierce, Rockford, IL, USA) according
to the manufacturer's instructions. For immunoblotting,
30 µg of total cellular protein per lane were separated by
standard SDS-PAGE on 15% gels and electrophoretically
transferred to PVDF membranes (Millipore, Eschborn,
Germany). After blocking in PBS containing 5% dry milk
and 0.05% Tween 20, acetylated histone H3 was immun-
odetected rabbit anti-acetylated histone H3 (dilution
1:10,000; Upstate Biotechnology, Lake Placid, NY, USA)
polyclonal antibodies. Peroxidase-conjugated goat anti-
rabbit IgGs (dilution 1:12,500; Dianova, Hamburg, Ger-
many) followed by enhanced chemiluminescence (Amer-
sham Biosciences, Freiburg, Germany) were used for
detection.
Results
Comparison of the cytotoxic activities of SAHA and 
paclitaxel on ovarian cancer cells
Initially, we compared the cytotoxic activities of SAHA
and paclitaxel by employing the ovarian carcinoma cell
lines OVCAR-3, SK-OV-3, and A2780. SAHA (1–20 µM)
and paclitaxel (3–300 nM) were applied in the same con-
centration range as has been used in other in vitro studies
on these agents. Cytotoxicity was monitored by Alamar
Blue assay. For all three cell lines, we observed a concen-
tration-dependent cytotoxic effect with increasing doses
of the two compounds (Fig. 1A). After treatment with 20
µM SAHA for 72 hours, 45–69% of cells remained viable;
after 72 hours of culture with 300 nM paclitaxel, cell via-
bility amounted to 53–75%. Hence, at the concentrations
applied, SAHA and paclitaxel induced comparable cyto-
toxicity in the three cell lines tested.
To compare the potential activities of SAHA and paclitaxel
against ovarian carcinoma cells ex vivo, we performed
cytotoxicity assays with cell isolates from five patients
with ovarian cancer. Four of the five ascites samples were
obtained from untreated patients, one had been treated
with a single dose of carboplatin/paclitaxel (ASC-OC-4).
As shown in Fig 1B, SAHA evoked a dose-dependent cyto-
toxic effect in all five isolates. A 72-h exposure to 20 µM
SAHA resulted in 21% (ASC-OC-1) to 63% (ASC-OC-4)
cell killing. In contrast, four of the five isolates were resist-
ant to paclitaxel (i.e., <10% cell death at 300 nM paclit-
axel for 72 hours). Only isolate ASC-OC-4 was susceptible
to this agent, with 21% cell killing observed at 72 hours
by 300 nM of paclitaxel. These ex vivo observations were
in part reflected by the clinical outcome of the chemother-
apy: the four patients who had been chemotherapeuti-
cally naive at the time of ascites fluid removal were
subsequently treated with six cycles of a paclitaxel/carbo-
platin combination therapy (paclitaxel at a dose of 175
mg/m2 and carboplatin at area under the concentration-
time curve of 5 mg/ml/min); in two of them (ASC-OC-1
and -3), no sign of response to treatment was noted.BMC Cancer 2006, 6:183 http://www.biomedcentral.com/1471-2407/6/183
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Comparison of the caspase-3-activating potencies of 
SAHA and paclitaxel
The activation of caspase-3 is a hallmark of apoptotic cell
death in many cell types [26]. Accordingly, its activity is
considered as an appropriate measure of cytotoxic respon-
siveness. We assessed whether SAHA and paclitaxel would
activate caspase-3 in ovarian cancer cells. First, we exam-
ined caspase-3 activities in OVCAR-3, SK-OV-3, and
A2780 cells: both SAHA and paclitaxel activated caspase-
3 in a concentration-dependent fashion in all three cell
lines (Fig. 2A). Second, we analyzed SAHA and paclitaxel
for their caspase-3-activating potencies in the patient-
derived ovarian cancer cells. As displayed in Fig. 2B, a 24-
h treatment with SAHA led to a dose-dependent increase
in caspase-3 activity in all five isolates, while a 24-h treat-
ment with paclitaxel had no effect on caspase-3 activity in
three of them.
Assessment of the cytotoxic effects of the combination of 
SAHA and paclitaxel on ovarian cancer cells
HDIs have been shown to favourably interact with other
treatment regimen, such as ionising radiation or chemo-
therapy [10]. We thus evaluated whether SAHA would
cooperate with paclitaxel in exerting cytotoxic effects on
ovarian cancer cells. OVCAR-3 and SK-OV-3 cells were
pretreated with 0.5, 1, or 2 µM SAHA for 4 hours, and cul-
tured with paclitaxel for further 72 hours. Cytotoxicity
was examined by Alamar Blue assay. As presented in Fig.
3, the combined treatment of SAHA and paclitaxel led to
an additive effect in SK-OV-3 cells and a less-than-additive
effect in OVCAR-3 cells.
Comparison of SAHA and paclitaxel to induce cell death in 
drug-resistant ovarian cancer cells
Resistance to chemotherapy is frequently associated with
the overexpression of ATP-binding cassette drug trans-
Cytotoxic activity of SAHA and paclitaxel on ovarian cancer cells Figure 1
Cytotoxic activity of SAHA and paclitaxel on ovarian cancer cells. A, ovarian cancer cell lines; B, patient-derived ovarian can-
cer cells. Cells were incubated with SAHA or paclitaxel for 72 hours, and cytotoxic effects were assessed by Alamar Blue 
assay. Cell viabilities are expressed as the ratio of absorbance of treated to untreated cells. Means ± SD of 2 (ASC-OC-1), 3 
(ASC-OC-2 to ASC-OC-5), or 4 (cell lines) independent experiments in quadruplicates are shown.
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porter proteins like Pgp [27]. To investigate the role of Pgp
overexpression for the responsiveness of ovarian cancer
cells to SAHA and paclitaxel, we employed a drug-resist-
ant variant of the A2780 cell line, the Pgp-overexpressing
2780AD cells [28]. Fig. 4 shows that 2780AD cells were
totally resistant to paclitaxel at the doses applied (100 nM
paclitaxel for 72 hours). In contrast, a 72-h treatment with
SAHA evoked a pronounced cytotoxic effect on these cells,
with up to 49% cell killing. In addition, we assessed
whether the paclitaxel resistance as well as the SAHA sen-
sitivity could be modulated by the Pgp inhibitor CsA. As
demonstrated in Fig. 4, preadministration of 10 µM CsA
potently restored the cytotoxic activity of paclitaxel on
2780AD cells, resulting in up to 59% cell death. With
respect to SAHA, CsA caused a moderate enhancement of
cell killing in 2780AD cells, with a maximum 2.6-fold
amplification of SAHA's cytotoxicity being observed at 2
and 5 µM SAHA.
SAHA treatment leads to histone hyperacetylation in 
ovarian cancer cells
The effect of SAHA on histone acetylation was examined
in order to confirm that it had effectively inhibited the
enzymatic activity of histone deacetylases. Firstly,
OVCAR-3, SK-OV-3, and A2780 cells were incubated with
10 µM SAHA or 100 nM paclitaxel for 24 hours, and the
acetylation status of histone H3 was analyzed by Western
blot using an acetylated H3-specific antibody: treatment
with SAHA induced histone H3 hyperacetylation in all
three cell lines (Figure 5). Secondly, three of the five
ascites samples were exposed to either 5 or 20 µM SAHA
(ASC-OC-1 and -3) or to 20 µM SAHA or 100 nM paclit-
axel (ASC-OC-2) for 24 hours: SAHA induced a dose-
dependent accumulation of acetylated histone H3 in the
patient-derived cancer cells. Paclitaxel had no effect on the
acetylation status of H3, neither in the cell lines nor in the
ascites sample tested.
Effect of SAHA and paclitaxel on caspase-3 activity in ovarian cancer cells Figure 2
Effect of SAHA and paclitaxel on caspase-3 activity in ovarian cancer cells. A, ovarian cancer cell lines; B, patient-derived ovar-
ian cancer cells. Cells were incubated with SAHA or paclitaxel for 24 hours, and caspase-3 activity was measured using the 
fluorogenic substrate Ac-DEVD-AFC. Relative caspase-3 activities are the ratio of treated cells to untreated cells. Means ± SD 
of 1 (ASC-OC-2 SAHA), 2 (ASC-OC-1, ASC-OC-2 paclitaxel, ASC-OC-4), or 3 (ASC-OC-3, ASC-OC-5, cell lines) independ-
ent experiments are shown.
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Discussion
To the best of our knowledge, this is the first study that
systematically compares an HDI and a conventional
chemotherapeutic agent for their treatment efficacy in
patient-derived cancer cells. HDIs hold promise as a pow-
erful new generation of anticancer drugs. Numerous in
vitro and animal studies have demonstrated that they can
induce differentiation and apoptosis, inhibit cell prolifer-
ation, and exert immune stimulatory and antiangiogenic
activities [reviewed in [7,8,10,29]]. HDIs have also been
shown to enhance the antitumour efficiency of other ther-
apeutic regimens, such as ionizing radiation or chemo-
therapy. In addition, early-phase clinical trials indicate
that HDIs have anticancer activity in a variety of solid and
haematological malignancies. However, despite all these
studies supporting the development of HDIs for clinical
use, no superiority of these agents over conventional anti-
neoplastic agents has yet been directly proven. Here we
present evidence that SAHA might be more effective than
paclitaxel in the treatment of ovarian cancer.
In order to establish the doses of SAHA and paclitaxel that
would induce comparable cell killing in ovarian cancer
cells, we initially monitored the cytotoxic activity of these
compounds in three ovarian cancer cell lines. SAHA at
concentrations of 1 to 20 µM was found to be as efficient
in eliciting cell death as paclitaxel at concentrations of 3
to 300 nM. The killing efficiency of the latter was observed
to saturate at 100 to 300 nM. This observation is in con-
cordance with findings in clinical studies, in which pacli-
taxel did not seem to show dose-related efficacy in
patients with ovarian cancer [30]. In the patient-derived
ovarian cancer cells, SAHA and paclitaxel were of very dif-
ferent effectiveness: while all five isolates responded to
SAHA, four of them were unresponsive to paclitaxel. This
observation made ex vivo had a correlative in vivo: two
patients were resistant to paclitaxel/carboplatin treat-
ment. However, the number of patient samples used was
rather small; thus, this study should not be generalised
without additional analyses. The doses of SAHA required
to induce cell death in the patient-derived cells were rela-
tively high (5–20 µM); these concentrations would be dif-
ficult to achieve in patients without severe toxic side
effects [16,18]. Yet, this limitation may be overcome by
intraperitoneal administration of SAHA allowing to
increase the dose without increasing systemic adverse side
effects. An advantage of intraperitoneal chemotherapy in
the treatment of ovarian cancer has already been demon-
strated in clinical trials [31-33]. Since HDIs have been
shown to cooperate with other treatment regimen in
exerting antitumour effects [10], we also assessed whether
SAHA would enhance the cytotoxic activity of paclitaxel in
ovarian cancer cells. Yet, no more than additive effects
were seen with this combination treatment. However, this
observation is consistent with recent studies, which show
that pretreatment with HDIs can enhance the cytotoxicity
of DNA-targeting agents such as etoposide, but not that of
drugs which do not target the DNA, like the antimetabo-
lite 5-fluorouracil or the microtubule-active vincristine
[34,35].
Treatment failure in ovarian cancer therapy is largely due
to chemotherapy resistance [3]. One hallmark of chem-
oresistance is the overexpression of the Pgp drug efflux
pump, which confers resistance to a variety of drugs
including the taxanes [27]. Here, we have demonstrated
that Pgp-overexpressing 2780AD cells are indeed fully
resistant to paclitaxel but sensitive to SAHA. This is con-
Combination effect of SAHA and paclitaxel on ovarian cancer cells Figure 3
Combination effect of SAHA and paclitaxel on ovarian cancer cells. Four hours after treatment with SAHA, OVCAR-3 and SK-
OV-3 cells were exposed to paclitaxel for further 72 hours. Cytotoxic effects were assessed by Alamar Blue assay. Cell viabili-
ties are expressed as the ratio of absorbance of treated to untreated cells. Means ± SD of 3 independent experiments in quad-
ruplicates are shown.
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sistent with previous findings in which SAHA was shown
to induce cell death in Pgp-expressing T-cell leukaemia
and colon carcinoma cells [36,37]. So, our data on ovar-
ian cancer cells further substantiate that SAHA is capable
of killing cancer cells irrespective of their Pgp status. How-
ever, although Pgp expression correlates to chemoresist-
ance in vitro, its in vivo significance in ovarian cancer is
unclear [3]. But as histone hypoacetylation is involved in
the silencing of a number of chemotherapeutic sensitivity
genes, a concerted reexpression of such genes – as accom-
plished by SAHA as well as other HDIs – holds promise to
overcome resistance [38].
The importance of caspases for SAHA- [39] as well as for
paclitaxel-induced cell death is a controversial issue. Some
reports point to a critical role of caspases for SAHA-medi-
ated cell death [35,40,41], whereas others suggest a cas-
pase-independent mechanism [37,42]. Likewise,
paclitaxel-triggered cell death has been reported to pro-
ceed in a caspase-dependent [43,44] or -independent
[45,46] manner. Here, in using the activation of caspase-
3 as a measure of cytotoxic responsiveness, we do not wish
to imply that caspase-3 activation would be a necessary
prerequisite for SAHA- or paclitaxel-induced cell death.
Clearly, the sheer activation of a caspase does not neces-
sarily implicate its requirement for cell death. As a matter
of fact, we did not observe a strict correlation between
cytotoxic response and caspase-3 activation, especially in
the cell lines: for example, while SAHA and paclitaxel
induced comparable cytotoxicity in OVCAR-3 and SK-OV-
3 cells, SAHA provoked a much higher increase in caspase-
3 activity in these cell lines. Nevertheless, the caspase-3
activities observed in the patient-derived cancer cells cor-
Effect of SAHA and paclitaxel on the acetylation status of his- tone H3 Figure 5
Effect of SAHA and paclitaxel on the acetylation status of his-
tone H3. Cells were treated with SAHA or paclitaxel for 24 
hours. Total protein (30 µg) was separated by a 15% polyacr-
ylamid gel. Western blot analyses were performed with anti-
bodies against acetylated histone H3.
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Effect of SAHA and paclitaxel on drug-resistant 2780AD cells Figure 4
Effect of SAHA and paclitaxel on drug-resistant 2780AD cells. CsA was applied 1 hour before SAHA or paclitaxel, cells were 
then incubated for 72 hours. Cell death was determined by cytofluorometric analysis of PI uptake. Means ± SD of 3 independ-
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roborate the data obtained by Alamar Blue assay: caspase-
3 activity was induced by SAHA in all five isolates, but in
only two of them by paclitaxel.
Conclusion
In conclusion, we have shown that SAHA is able to kill
paclitaxel-resistant ovarian cancer cells from patients.
Since SAHA induced cell death ex vivo, it might be a prom-
ising agent for ovarian cancer therapy in vivo. However,
such conclusion should be taken cum grano salis due to
the small number of patient samples analysed in our
study. Nonetheless, as two of the patients showed no
response to paclitaxel/carboplatin treatment, it is tempt-
ing to speculate that these patients might have benefited
from treatment with SAHA.
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